Estimating the Global, Regional, and National Economic Costs of COVID-19 Vaccination During the COVID-19 Pandemic

Round 1

Reviewer 1 Report (Previous Reviewer 1)

Comments and Suggestions for Authors

NIL

Reviewer 2 Report (Previous Reviewer 2)

Comments and Suggestions for Authors

I have read the revised paper and the responses of the authors. I think the corrections and additions have satisfied my concerns with the paper and feel that it is now acceptable for publication. They did a very nice job with the revision and addressing my concerns.

This manuscript is a resubmission of an earlier submission. The following is a list of the peer review reports and author responses from that submission.

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

 

General comment. Could standardize the write up of COVID-19 or Covid-19 across the manuscript

Define all the abbreviations ie COVID-19, COVAX,  etc.

 

Abstract

Line 31. What is the deferent between consumed and used?

Comment kindly use AMRO, WPRO, AFRO and EURO instead of AMR WPR, AFR and EUR as O stand for office and I am sure you meant the region and not the office

Comment: EMR is not included in the results, any reason?

Line 46-47. This study provides a comprehensive assessment of the financial investments required for COVID-19 vaccination, highlighting the costs borne by countries globally.

Comment: this para is study objective and the best place is in introduction and not conclusion.

In conclusion you should start with key study finding following the way forward. Please revisit the conclusion

 

Line 52-53. With more than 700 million confirmed cases and more than 6 million deaths worldwide by April 20231

Comment: Update the data

Line 58. Write SARS-CoV-2 in full

Comment: Could you also add the prequalification of COVID-19 vaccines by the WHO?

Line 72-74  and line 90.  Provide the reference

Methods

Define Low, low middle-income, middle-income and upper-middle-income countries

 

Discussions

Lines 340-351. I believe these are paragraphs are the repetition of the results, should be omitted

Conclusions

 

The conclusion lines 449-453, the paragraphs are a repetition of the results, revisit

Author Response

Thank you for your comments. Please see the attached.

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

Were the cost data normalized to account for differences among countries?

The conclusions section needs to be developed further. Emphasize why the paper is important, how can the results be used to impact public policy, etc. 

Otherwise, the paper is well done

Author Response

Thank you for your comments. Please see the attached.

Author Response File: Author Response.pdf

Reviewer 3 Report

Comments and Suggestions for Authors

Dear Authors,

Thank you for the opportunity to review your manuscript.
My observations are follows.

 
> Outline of the manuscript

This manuscript describes comprehensive research outcomes on COVID-19 vaccine cost estimate by combining public data with emphasis on region divided into high, upper middle, lower middle, and low-income countries. The result highlighted the economic burdens from vaccine procurement costs in low-income countries.

 

> Evaluation of the article

The manuscript provides comprehensive feature of costs for vaccine campaign. The manuscript reports mainly observation of feature.

 

Strengths: This manuscript provides comprehensive overview on the relationship between economy and vaccination provided by consistent estimation.

 

Weakness:

a)      Only reporting the observation of feature limits the value of the study.

b)     Meaning of the procurement per capta is unclear. Firstly, cost per capita is largely affected by dose per capta. Secondly, procurement cost depends on local cost for transportation cost may be low in low-income country.

 

Concrete comments follow.

 

Concrete Major Comments

1)     Suggestion: Any analysis supporting the hypothesis that procurement cost is limiting dose in low-income counties would add value to the research.

2)     Emphasizing cost per dose classified by incomes is recommended rather than cost per capita.

 

 

Minor comment

3)     Figure2. What is represented in chart (interquartile range and max-min?) should be explained.

Author Response

Thank you for your comments. Please see the attached.

Author Response File: Author Response.pdf